The effects of sesame, canola, and sesame–canola oils on cardiometabolic markers in patients with type 2 diabetes: a triple-blind three-way randomized crossover clinical trial

Mojgan Amiri, Hamidreza Raeisi-Dehkordi, Fatemeh Moghtaderi, Alireza Zimorovat, Matin Mohyadini, Amin Salehi-Abargouei*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Aims: To compare the effects of replacing regular dietary oils intake with sesame (SO), canola (CO), and sesame–canola (SCO) oils (a novel blend), on cardiometabolic markers in adults with type 2 diabetes mellitus (T2DM), in a triple-blind, three-way, randomized, crossover clinical trial. Methods: Participants were assigned to receive SO, CO, and SCO in three 9-week phases (4 weeks apart). Cardiometabolic makers (serum lipids, Apolipoprotein, cardiovascular risk scores, kidney markers, and blood pressure) were considered at the beginning and the end of intervention phases. Results: Ninety-two, ninety-five, and ninety-five participants completed the SO, SCO, and CO periods, respectively. After CO consumption, serum Apo A-1 concentrations were significantly higher compared with the SCO period in the whole population (p < 0.05). A considerable reduction in visceral adiposity index values was seen in the CO compared with the SO period in males (p < 0.05). Serum high-density lipoprotein concentration was also significantly higher after the SO intake compared with SCO in females (p < 0.05). The between-period analysis showed a substantial reduction in diastolic blood pressure in the SCO period compared with the CO and SO periods and lower systolic blood pressure after SCO versus CO intake in males (p < 0.05). Conclusions: Canola oil might protect CVD through improving Apo A-1 levels in patients with T2DM (particularly in females) and visceral adiposity index in male patients. However, the blend oil might beneficially affect blood pressure in men. Future sex-specific studies might warrant the current findings. Registry of clinical trials: This trial was registered in the Iranian Registry of Clinical Trials (IRCT, registration ID: IRCT2016091312571N6).

Original languageEnglish
Pages (from-to)3499-3516
Number of pages18
JournalEuropean Journal of Nutrition
Volume61
Issue number7
DOIs
Publication statusPublished - Oct 2022
Externally publishedYes

Bibliographical note

Funding Information:
The current study was funded by Shahid Sadoughi University of Medical Sciences ( http://www.ssu.ac.ir ) and Neshatavar food industry (Datis Corporation; http://www.neshatavar.com/?l=EN ). Datis Corporation also provided all the treatment oils consumed during the study including canola, sesame, sesame–canola and sunflower oils. Datis Corporation had no role in design and conduct of this manuscript; collection, management, analysis, and interpretation of the data; and preparation of this manuscript.

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Fingerprint

Dive into the research topics of 'The effects of sesame, canola, and sesame–canola oils on cardiometabolic markers in patients with type 2 diabetes: a triple-blind three-way randomized crossover clinical trial'. Together they form a unique fingerprint.

Cite this